TRGV9 and acute myeloid leukemia: In AML, promising data have been recently presented by Ganesan et al. demonstrating increased in vitro and in vivo γδ T cell-mediated cytotoxicity by a bispecific engager molecule against T cell receptor gamma variable 9 (TRGV9) and CD123 (51).